KG

Katta Geethanjali

Active Director Director DIN 10747872
DIN 10747872 First appointment Aug 2024 Primary industry Healthcare
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Katta Geethanjali

Data last updated:

Katta Geethanjali is a Director at Consia Pharmaceuticals Private Limited (since 2024). The company operates in Healthcare.

DIN 10747872
Primary Designation Director
Industry Healthcare
First Appointment 20 Aug 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director20 Aug 20242024Active

Directorship timeline

Open interactive timeline →
Consia Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Katta Geethanjali

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Katta Geethanjali

Katta Geethanjali currently holds 1 directorship: Consia Pharmaceuticals Private Limited (Director, since 20 Aug 2024).

Katta Geethanjali was first appointed on 20 Aug 2024 as Director at Consia Pharmaceuticals Private Limited.

The current boards of Katta Geethanjali's companies include Kommaboina Rohini (Consia Pharmaceuticals Private Limited), Sri Sai Pavana Vihari Uppalapati (Consia Pharmaceuticals Private Limited), Udaya Lakshmi Yama (Consia Pharmaceuticals Private Limited), Uppalapati Anjana (Consia Pharmaceuticals Private Limited), Venkata Sai Harsha Gajula (Consia Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available